French National Agency For Research On Aids And Viral Hepatitis

This study tested whether adding prazosin, a drug usually used for high blood pressure, to standard hepatitis C treatment could reduce liver scarring. 112 adults with chronic hepatitis C (genotype 1 or 4) and severe liver fibrosis took part. Researchers measured changes in liver …

This study tested whether adding Interleukin-2 (IL-2) to standard HIV drugs could increase CD4 immune cells in patients whose current treatment was failing and who had very low CD4 counts (≤200). Fifty-seven adults with HIV-1 took part. The main goal was to see if their CD4 count…

This study tested a once-daily combination of three HIV drugs (tenofovir, emtricitabine, and efavirenz) in 70 adults with both HIV and tuberculosis. Participants had not taken HIV medication before and had been on TB treatment for less than three months. The goal was to see if th…

This study tested a combination of three drugs (pegylated interferon, ribavirin, and boceprevir) in 58 adults with genotype 1 hepatitis C and cirrhosis who were waiting for a liver transplant. The goal was to see if the treatment could clear the virus before surgery. The study me…

This study tested two versions of the H1N1 flu vaccine in 306 people living with HIV. One vaccine included an adjuvant (a booster ingredient) and the other did not. The goal was to see which vaccine was safer and better at protecting against the flu. Participants were followed fo…

This study tested whether adding the drug maraviroc to standard HIV treatment could help improve immune function in people whose CD4 counts remain low even when the virus is well-controlled. It involved 60 HIV-positive adults with low CD4 counts and little recent immune improveme…

This study tested a drug called interleukin-2 (IL-2) in 10 people with hepatitis C-related vasculitis that did not get better with usual treatments. The goal was to see if IL-2 could boost the body's immune regulation and control the disease. Participants received IL-2 injections…

This study tested whether HIV patients with long-term viral suppression could switch to a single boosted drug (darunavir/r) instead of staying on a standard combination of drugs. 225 adults with well-controlled HIV took part. The goal was to see if the single-drug approach could …

This study tested whether adding an extra HIV drug (enfuvirtide) to standard treatment for 6 months helps people with very low CD4 counts recover their immune system faster. It included 195 adults newly diagnosed with HIV who had a high risk of getting AIDS. The goal was to see i…

This study looked at whether people with HIV who have their virus under control can switch from the injectable drug enfuvirtide to the oral pill raltegravir. 170 participants were randomly assigned to either stay on their current treatment or switch to raltegravir. The goal was t…

This study looked at 35 people with HIV who had never taken HIV drugs before. They all received a daily combination of three medications (atazanavir, ritonavir, tenofovir/emtricitabine) in special bottles that recorded every time they opened them. The goal was to measure how much…

This study looked at whether adding vitamin D to standard hepatitis C treatment could help patients with genotype 1 or 4 who had not responded to previous therapy. 32 adults with low vitamin D levels were enrolled. The goal was to see if vitamin D could make the antiviral drugs w…

This study tested whether adding a powerful HIV drug called FUZEON® to standard antiretroviral therapy could help people with HIV who also have a rare brain infection called PML. PML is caused by a virus that attacks the brain when the immune system is weak. The goal was to see i…

This study tests whether interleukin-2 (IL-2) can help maintain CD4 cell counts in people with HIV who have not yet started antiretroviral therapy. 130 participants with CD4 counts between 300 and 500 will receive IL-2 injections. The goal is to see if IL-2 can delay the need for…

This study tested whether alendronate, a drug used for osteoporosis, can improve bone density in people with HIV. 140 participants received either alendronate or a placebo, along with calcium and vitamin D, for 2 years. The goal was to see if the drug could strengthen bones and r…

This study tested two different two-drug combinations in 61 HIV patients who had never taken protease inhibitors before. The goal was to see if these combinations could lower the amount of virus in the blood to very low levels (below 50 copies/mL) after 16 weeks. The study also c…

This study tests whether a DNA vaccine can help people with chronic hepatitis B control the virus after they stop taking standard antiviral drugs. The vaccine aims to boost the immune system to delay the virus from becoming active again. The trial involves 70 adults who have unde…

This study tested two statin drugs, rosuvastatin and pravastatin, in 86 people with HIV who also had high cholesterol. The goal was to see which drug lowered LDL (bad) cholesterol better and was safer when taken with HIV medications. Participants took one of the two statins for 4…

This study looked at 167 men who have sex with men and are on HIV treatment with undetectable virus in their blood. Researchers took blood and semen samples to see if the virus could still be found in semen. The goal was to understand if there is still a risk of passing HIV to ot…

This study looked at whether it is possible and practical to offer rapid HIV testing to men who have sex with men (MSM) in community settings, rather than only at clinics. Researchers worked with teams in France and Canada to test this approach with 357 participants. The goal was…

This study surveyed 596 people in France who were newly diagnosed with HIV. The goal was to find out why they did not use pre-exposure prophylaxis (PrEP), a medicine that prevents HIV infection. By understanding these missed opportunities, researchers hope to improve how PrEP is …